Q2 25 EPS
$-1.12
BEAT +16.12%
Est. $-1.34
Q2 25 Revenue
$66.8M
BEAT +3,131.07%
Est. $2.1M
vs S&P Since Q2 25
+119.5%
BEATING MARKET
CYTK +136.5% vs S&P +17.0%
Market Reaction
Did CYTK Beat Earnings? Q2 2025 Results
Cytokinetics delivered a sharply better-than-expected second quarter, with revenue of $66.77 million demolishing the $2.07 million consensus estimate by 3,131.07% and surging 26,714.9% from just $249,000 a year ago, as a $52.40 million recognition fr… Read more Cytokinetics delivered a sharply better-than-expected second quarter, with revenue of $66.77 million demolishing the $2.07 million consensus estimate by 3,131.07% and surging 26,714.9% from just $249,000 a year ago, as a $52.40 million recognition from its Bayer license and collaboration agreement for aficamten in Japan, combined with $11.70 million in clinical milestone payments, reshaped the top line almost overnight. The loss per share of $1.12 also came in well ahead of the $1.34 consensus estimate, a 16.12% beat, though the company still posted a net loss of $134.37 million as R&D spending climbed to $112.55 million and G&A costs reached $65.72 million, both reflecting aggressive commercial readiness investments ahead of aficamten's December 26, 2025 PDUFA date. Management held its full-year operating expense guidance steady at $670 million to $710 million, signaling confidence in its spending trajectory as a late-cycle FDA meeting approaches in September and MAPLE-HCM primary results head to the ESC Congress in August.
Key Takeaways
- • Recognition of $52.4 million from Bayer license and collaboration agreement for aficamten in Japan
- • $11.7 million in clinical milestones from non-obstructive and obstructive HCM trials in Japan
- • $75 million drawn from Tranche 4 of Royalty Pharma Multi Tranche Term Loan
CYTK YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
CYTK Revenue by Segment
With YoY comparisons, source: SEC Filings
“Following solid progress in the first half of the year, we are looking forward to several key corporate milestones. Our primary focus remains on preparations for the potential FDA approval of aficamten in late December and subsequent commercial launch in early 2026.”
— Robert I. Blum, Q2 2025 Earnings Press Release
CYTK Earnings Trends
CYTK vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CYTK EPS Trend
Earnings per share: estimate vs actual
CYTK Revenue Trend
Quarterly revenue: estimate vs actual
CYTK Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-1.63 | $-1.67 | -2.31% | $19.4M | +113.25% |
| Q4 25 MISS FY | $-1.37 | $-1.50 | -9.67% | $17.8M | +121.30% |
| FY Full Year | — | $-6.54 | — | $88.0M | — |
| Q3 25 MISS | $-1.63 | $-2.55 | -56.33% | $1.9M | -69.88% |
| Q2 25 BEAT | $-1.34 | $-1.12 | +16.12% | $66.8M | +3,131.07% |
| Q1 25 BEAT | $-1.36 | $-1.36 | +0.23% | $1.6M | -39.51% |